ReviewNature reviews. Nephrology2022
COVID-19 and kidney disease: insights from epidemiology to inform clinical practice.
Review in Nature reviews. Nephrology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 2 syntheses or guidelines pooled it, 86 citations in OpenAlex.
- Long-term renal outcomes of patients with COVID-19: a meta-analysis of observational studies.Journal of nephrology · 2023Pooled it
- The Impact of the COVID-19 Pandemic on Patients With CKD: Systematic Review of Qualitative Studies.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2023Pooled it
- Associations of Pre-Pandemic CKD With Acute and Post-Acute COVID-19: The C4R Study.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2026Article
- End-of-life care planning for ethnically diverse kidney patients in the COVID-19 era.BMC nephrology · 2026Article
- Multiscale bone remodeling in COVID-19: from osteoimmune signaling to structural and mechanical impairment.Frontiers in bioengineering and biotechnology · 2026Review
- Long-term kidney outcomes after COVID-19: a matched cohort study using the OpenSAFELY platform.The Lancet regional health. Europe · 2025Article
- Evolving impact of the COVID-19 pandemic in chronic dialysis recipients in France.Communications medicine · 2025Article
- Chronic kidney disease amplifies severe kidney injury and mortality in a mouse model of skin arsenical exposure.American journal of physiology. Renal physiology · 2025Article
- Investigation of renal function in patients with long COVID in the Amazon region: a cross-sectional study.BMC infectious diseases · 2025Observational
- Risk factors for relapse and aggravation in membranous nephropathy after COVID-19 infection.BMC nephrology · 2025Article
- Viral nucleic acid load in the milk of lactating mothers with COVID-19 and the prognosis of infants.Scientific reports · 2025Article
- Anthraquinones fromDrug design, development and therapy · 2025Review
- Development Of the VAMPCT Score for Predicting Mortality in CKD Patients with COVID-19.International journal of medical sciences · 2025Article
- The survival of B cells is compromised in kidney disease.Nature communications · 2024Article
- Kidney Function Decline After COVID-19 Infection.JAMA network open · 2024Article
- Integrated Transcriptomic Analysis Reveals Reciprocal Interactions between SARS-CoV-2 Infection and Multi-Organ Dysfunction, Especially the Correlation of Renal Failure and COVID-19.Life (Basel, Switzerland) · 2024Article
- Clinical characteristics and outcomes of hospitalized kidney transplant recipients with COVID-19 infection in China during the Omicron wave: a single-center cohort study.Journal of Zhejiang University. Science. B · 2024Article
- Mesenchymal stem cells and their derived exosomes for the treatment of COVID-19.World journal of stem cells · 2024Review
- Kidney Function Tests and Continuous eGFR Decrease at Six Months after SARS-CoV-2 Infection in Patients Clinically Diagnosed with Post-COVID Syndrome.Biomedicines · 2024Article
- Are Kidneys Affected by SARS-CoV-2 Infection? An Updated Review on COVID-19-Associated AKI.Pathogens (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 6 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the course of the COVID-19 pandemic, numerous studies have aimed to address the challenges faced by patients with kidney disease and their caregivers. These studies addressed areas of concern such as the high infection and mortality risk of patients on in-centre haemodialysis and transplant recipients. However, the ability to draw meaningful conclusions from these studies has in some instances been challenging, owing to barriers in aspects of usual care, data limitations and problematic methodological practices. In many settings, access to SARS-CoV-2 testing differed substantially between patient groups, whereas the incidence of SARS-CoV-2 infection varied over time and place because of differences in viral prevalence, targeted public health policies and vaccination rates. The absence of baseline kidney function data posed problems in the classification of chronic kidney disease and acute kidney injury in some studies, potentially compromising the generalizability of findings. Study findings also require attentive appraisal in terms of the effects of confounding, collider bias and chance. As this pandemic continues and in the future, the implementation of sustainable and integrated research infrastructure is needed in settings across the world to minimize infection transmission and both prevent and plan for the short-term and long-term complications of infectious diseases. Registries can support the real-world evaluation of vaccines and therapies in patients with advanced kidney disease while enabling monitoring of rare complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.